Diagnosis and Management of Recurrent and Complicated UTIs in Women: Controversies and Dilemmas

Article Type
Changed
Thu, 12/12/2024 - 15:45

In this piece, Dr. Mickey Karram & Dr. Roger R. Dmochowski discuss how although UTIs have demonstrated widespread occurrence and significant healthcare costs, there is not yet a “gold standard” definition for complicated UTI. To avoid the overuse of antimicrobial agents and their associated issues, it is vital that clinicians evaluate test results in the context of a patient’s overall risk and history of UTIs and current clinical presentation and utilize testing that enables more informed decisions.

Click here to read more

Sponsor
Developed under the direction and sponsorship of Pathnostics.
Publications
Sections
Sponsor
Developed under the direction and sponsorship of Pathnostics.
Sponsor
Developed under the direction and sponsorship of Pathnostics.

In this piece, Dr. Mickey Karram & Dr. Roger R. Dmochowski discuss how although UTIs have demonstrated widespread occurrence and significant healthcare costs, there is not yet a “gold standard” definition for complicated UTI. To avoid the overuse of antimicrobial agents and their associated issues, it is vital that clinicians evaluate test results in the context of a patient’s overall risk and history of UTIs and current clinical presentation and utilize testing that enables more informed decisions.

Click here to read more

In this piece, Dr. Mickey Karram & Dr. Roger R. Dmochowski discuss how although UTIs have demonstrated widespread occurrence and significant healthcare costs, there is not yet a “gold standard” definition for complicated UTI. To avoid the overuse of antimicrobial agents and their associated issues, it is vital that clinicians evaluate test results in the context of a patient’s overall risk and history of UTIs and current clinical presentation and utilize testing that enables more informed decisions.

Click here to read more

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry-Sponsored Supplement.
Gate On Date
Wed, 05/10/2023 - 11:00
Un-Gate On Date
Wed, 05/10/2023 - 11:00
Use ProPublica
CFC Schedule Remove Status
Wed, 05/10/2023 - 11:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 12/12/2024 - 15:45
Activity Salesforce Deliverable ID
378784.1
Product Name
Promo - Frontline - MDedge ObGyn PDF

Forget Fibrates for Cardiovascular Risk Reduction: Commentary on the Failure and Implications of the PROMINENT Trial

Article Type
Changed
Thu, 12/12/2024 - 15:46

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

 

Read More 

 

 

 

 

Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc.
Publications
Sections
Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc.
Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc.

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

 

Read More 

 

 

 

 

In this supplement to Family Medicine, Charles P Vega, MD, and Pamela R Kushner, MD, discuss failure of the PROMINENT trial and implications for use of fibrates to reduce cardiovascular risk.

 

Read More 

 

 

 

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry - Sponsored Supplement
Gate On Date
Wed, 04/12/2023 - 09:30
Un-Gate On Date
Wed, 04/12/2023 - 09:30
Use ProPublica
CFC Schedule Remove Status
Wed, 04/12/2023 - 09:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 12/12/2024 - 15:46
Activity Salesforce Deliverable ID
377933.2

Mycoplasma genitalium: A Pathogen We Can Finally Begin to Understand

Article Type
Changed
Thu, 12/12/2024 - 15:49
image of the cover of a PDF suppliment

Riding alongside known STIs, this historically elusive microbe may have often been the underlying cause of a variety of symptoms. In this supplement to OBG Management Dr. Kyle Bukowski discusses how to meet the challenge presented by this not-so-new microbe while helping foster regular STI testing, and encourage patients to seek care when symptoms occur.

Click Here to Read the Supplement

Sponsor
DEVELOPED UNDER THE DIRECTION AND SPONSORSHIP OF HOLOGIC. THIS CONTENT WAS PREP…
Publications
Sections
Sponsor
DEVELOPED UNDER THE DIRECTION AND SPONSORSHIP OF HOLOGIC. THIS CONTENT WAS PREP…
Sponsor
DEVELOPED UNDER THE DIRECTION AND SPONSORSHIP OF HOLOGIC. THIS CONTENT WAS PREP…
image of the cover of a PDF suppliment

Riding alongside known STIs, this historically elusive microbe may have often been the underlying cause of a variety of symptoms. In this supplement to OBG Management Dr. Kyle Bukowski discusses how to meet the challenge presented by this not-so-new microbe while helping foster regular STI testing, and encourage patients to seek care when symptoms occur.

Click Here to Read the Supplement

image of the cover of a PDF suppliment

Riding alongside known STIs, this historically elusive microbe may have often been the underlying cause of a variety of symptoms. In this supplement to OBG Management Dr. Kyle Bukowski discusses how to meet the challenge presented by this not-so-new microbe while helping foster regular STI testing, and encourage patients to seek care when symptoms occur.

Click Here to Read the Supplement

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry-Sponsored Supplement
Gate On Date
Fri, 02/24/2023 - 17:15
Un-Gate On Date
Fri, 02/24/2023 - 17:15
Use ProPublica
CFC Schedule Remove Status
Fri, 02/24/2023 - 17:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 12/12/2024 - 15:49
Activity Salesforce Deliverable ID
SF379121.1
Product Name
Promo - Frontline - MDedge ObGyn PDF

Frontline STI Screening Starts with Primary Care

Article Type
Changed
Thu, 12/12/2024 - 15:51

In this supplement to Family Practice, Heather M. Territo, MD, and Gale R. Burstein, MD, MPH discuss how primary care physicians play an essential role in screening for STIs in young patients. 

 

Read More 








 

 

Sponsor
Developed under the direction and sponsorship of Hologic Diagnostics. This cont…
Publications
Sections
Sponsor
Developed under the direction and sponsorship of Hologic Diagnostics. This cont…
Sponsor
Developed under the direction and sponsorship of Hologic Diagnostics. This cont…

In this supplement to Family Practice, Heather M. Territo, MD, and Gale R. Burstein, MD, MPH discuss how primary care physicians play an essential role in screening for STIs in young patients. 

 

Read More 








 

 

In this supplement to Family Practice, Heather M. Territo, MD, and Gale R. Burstein, MD, MPH discuss how primary care physicians play an essential role in screening for STIs in young patients. 

 

Read More 








 

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry-Sponsored Supplement
Gate On Date
Tue, 02/28/2023 - 11:00
Un-Gate On Date
Tue, 02/28/2023 - 11:00
Use ProPublica
CFC Schedule Remove Status
Tue, 02/28/2023 - 11:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 12/12/2024 - 15:51
Activity Salesforce Deliverable ID
364683.2

Non-Surgical Treatment of Heavy Menstrual Bleeding From Fibroids: A New Paradigm

Article Type
Changed
Thu, 12/12/2024 - 15:52

GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.

After reading this short article, you have an opportunity to earn 1.0 CME credits.

Click here to read more

Sponsor
This program is supported by an unrestricted educational grant provided by Myov…
Publications
Sections
Sponsor
This program is supported by an unrestricted educational grant provided by Myov…
Sponsor
This program is supported by an unrestricted educational grant provided by Myov…

GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.

After reading this short article, you have an opportunity to earn 1.0 CME credits.

Click here to read more

GnRH antagonists with estrogen/progesterone are promising new uterine-sparing options for treating uterine fibroids. Two experts review data from two recent clinical trials to bring you up to speed on the benefits and risks of this treatment approach.

After reading this short article, you have an opportunity to earn 1.0 CME credits.

Click here to read more

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry - Sponsored CME Supplement
Gate On Date
Fri, 02/03/2023 - 13:30
Un-Gate On Date
Fri, 02/03/2023 - 13:30
Use ProPublica
CFC Schedule Remove Status
Fri, 02/03/2023 - 13:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 12/12/2024 - 15:52
Activity Salesforce Deliverable ID
SF365795.2

We Have the Tools to Prevent Cervical Cancer— So Why Are Rates Increasing?

Article Type
Changed
Thu, 12/12/2024 - 15:52

Cervical cancer screening is often hailed as the most successful screening program ever implemented. Despite these past successes, cervical cancer incidence is no longer decreasing and is actually rising significantly in younger women within the United States. In a country with a well-established screening program, effective screening tools, and HPV vaccination, it seems unfathomable that we are witnessing an increase in cervical cancers. This alarming trend should be cause for concern among all healthcare professionals.

 

Click here to read more

Sponsor
Developed under the direction and sponsorship of Hologic. This content was prep…
Publications
Sections
Sponsor
Developed under the direction and sponsorship of Hologic. This content was prep…
Sponsor
Developed under the direction and sponsorship of Hologic. This content was prep…

Cervical cancer screening is often hailed as the most successful screening program ever implemented. Despite these past successes, cervical cancer incidence is no longer decreasing and is actually rising significantly in younger women within the United States. In a country with a well-established screening program, effective screening tools, and HPV vaccination, it seems unfathomable that we are witnessing an increase in cervical cancers. This alarming trend should be cause for concern among all healthcare professionals.

 

Click here to read more

Cervical cancer screening is often hailed as the most successful screening program ever implemented. Despite these past successes, cervical cancer incidence is no longer decreasing and is actually rising significantly in younger women within the United States. In a country with a well-established screening program, effective screening tools, and HPV vaccination, it seems unfathomable that we are witnessing an increase in cervical cancers. This alarming trend should be cause for concern among all healthcare professionals.

 

Click here to read more

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry-Sponsored Supplement
Gate On Date
Fri, 12/09/2022 - 16:45
Un-Gate On Date
Fri, 12/09/2022 - 16:45
Use ProPublica
CFC Schedule Remove Status
Fri, 12/09/2022 - 16:45
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 12/12/2024 - 15:52
Activity Salesforce Deliverable ID
362990.2

Fourth Study to Show Consistent Benefit of Highly Purified Eicosapentaenoic Acid on Cardiovascular Outcomes: Results From RESPECT-EPA

Article Type
Changed
Thu, 12/12/2024 - 15:55

In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
 

Read More

 

Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc. This conte…
Publications
Sections
Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc. This conte…
Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc. This conte…

In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
 

Read More

 

In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
 

Read More

 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry - Sponsored Supplement
Gate On Date
Mon, 12/19/2022 - 14:30
Un-Gate On Date
Mon, 12/19/2022 - 14:30
Use ProPublica
CFC Schedule Remove Status
Mon, 12/19/2022 - 14:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 12/12/2024 - 15:55
Activity Salesforce Deliverable ID
SF377684.4

“The Nail in the Coffin for Fibrates”: Futility of PROMINENT Trial Definitively Settles Debate on Avoiding Use of Fibrate Class of Medications for Cardiovascular Risk Reduction

Article Type
Changed
Thu, 12/12/2024 - 15:58

In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction. 

 

Read More


 

Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc. This conte…
Publications
Sections
Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc. This conte…
Sponsor
Developed under the direction and sponsorship of Amarin Pharma, Inc. This conte…

In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction. 

 

Read More


 

In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction. 

 

Read More


 

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
Information from Industry - Sponsored Supplement
Gate On Date
Mon, 12/19/2022 - 13:30
Un-Gate On Date
Mon, 12/19/2022 - 13:30
Use ProPublica
CFC Schedule Remove Status
Mon, 12/19/2022 - 13:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Gating Strategy
No Gating
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Thu, 12/12/2024 - 15:58
Activity Salesforce Deliverable ID
377684.3